NCT00258011View on ClinicalTrials.gov

Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Mucopolysaccharidosis IHurler SyndromeHurler-Scheie SyndromeScheie Syndrome
Interventions
BIOLOGICAL

Aldurazyme (Recombinant Human Alpha-L-Iduronidase)

0.58 mg/kg every week

Trial Locations (2)

545-8586

Osaka City University Hospital, Osaka

157-8535

National Center for Child Health and Development, Tokyo

All Listed Sponsors
collaborator

BioMarin/Genzyme LLC

INDUSTRY

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00258011 - Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease | Biotech Hunter | Biotech Hunter